Issn Print: 1533-7006

Publication Date: 2004/10/01


Print

NEW INTEREST IN MAO INHIBITORS FOR PARKINSON DISEASE

Richard Robinson

    loading  Checking for direct PDF access through Ovid

Excerpt

ROME — Monoamine oxidase (MAO) inhibitors have a long history in Parkinson disease. But in the last few years, studies show that these drugs still can offer something new, including a new formulation – Zydis selegiline (a wafer form) – and two new agents, rasagiline and moclobemide. One study suggests that rasagiline may slow progression of the disease.
Movement disorder experts discussed these studies here this summer in a satellite symposium to the International Congress of Parkinson's Disease and Movement Disorders.

Related Topics

    loading  Loading Related Articles